- Home
- DHY vs XOMA Comparison
DHY vs XOMA Comparison
Compare DHY & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- XOMA
- Stock Information
- Founded
- DHY 1998
- XOMA 1981
- Country
- DHY United States
- XOMA United States
- Employees
- DHY N/A
- XOMA N/A
- Industry
- DHY Finance/Investors Services
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- XOMA Health Care
- Exchange
- DHY Nasdaq
- XOMA Nasdaq
- Market Cap
- DHY 218.7M
- XOMA 250.1M
- IPO Year
- DHY N/A
- XOMA N/A
- Fundamental
- Price
- DHY $2.13
- XOMA $19.93
- Analyst Decision
- DHY
- XOMA Strong Buy
- Analyst Count
- DHY 0
- XOMA 2
- Target Price
- DHY N/A
- XOMA $72.00
- AVG Volume (30 Days)
- DHY 569.1K
- XOMA 29.3K
- Earning Date
- DHY 01-01-0001
- XOMA 03-17-2025
- Dividend Yield
- DHY 9.10%
- XOMA N/A
- EPS Growth
- DHY N/A
- XOMA N/A
- EPS
- DHY N/A
- XOMA N/A
- Revenue
- DHY N/A
- XOMA $28,487,000.00
- Revenue This Year
- DHY N/A
- XOMA $29.60
- Revenue Next Year
- DHY N/A
- XOMA $34.18
- P/E Ratio
- DHY N/A
- XOMA N/A
- Revenue Growth
- DHY N/A
- XOMA 498.72
- 52 Week Low
- DHY $1.77
- XOMA $19.79
- 52 Week High
- DHY $2.08
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- DHY 45.51
- XOMA 31.42
- Support Level
- DHY $2.10
- XOMA $20.45
- Resistance Level
- DHY $2.15
- XOMA $21.45
- Average True Range (ATR)
- DHY 0.03
- XOMA 0.86
- MACD
- DHY -0.00
- XOMA 0.11
- Stochastic Oscillator
- DHY 49.67
- XOMA 6.67
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.